Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
CRISPR Therapeutics AG Logo

ARKG Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

TherapeuticsGene TherapyCAR-T Cell TherapyCRSPR Gene Editing
Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
December 29, 2022
BUY8.134k0.018%ARKG
December 28, 2022
BUY7.389k0.016%ARKG
December 27, 2022
BUY10.787k0.0231%ARKG
December 19, 2022
BUY5.708k0.0124%ARKG
December 16, 2022
BUY3.366k0.0075%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKGARKK$56.12
⚖️Weighting🧢Market Cap
3.63%$4.39b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
11311.82
🏋️‍♀️Weight Rank Across All Funds🌏Country
13🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$70.012.03%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Website
www.crisprtx.com